← Search & browse all drugs
NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Other antiepileptics
carisbamate
N03AX19
Forms & Strengths
- Investigation drug / Not FDA approved for commercial use
Adult Dosing
- No standard FDA-approved adult dosing available
- Studied in clinical trials as adjunctive therapy for partial-onset seizures at doses ranging from 200 mg to 800 mg twice daily
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
- No standard pediatric dosing recommendations available
Indications
- Investigated primarily as an adjunctive treatment for partial-onset seizures in adults with epilepsy
Mechanism of Action
- Dicarbamate derivative acting as an anticonvulsant
- Believed to modulate voltage-gated sodium channels and inhibit sustained repetitive neuronal firing
- May also modulate excitatory amino acid release
Contraindications
- Hypersensitivity to carisbamate or any component of the formulation
Adverse Reactions
- Somnolence
- Dizziness
- Headache
- Fatigue
- Nausea
- Diplopia
- Ataxia
Drug Interactions
- Potential for pharmacokinetic interactions with hepatic enzyme inducers or inhibitors due to CYP metabolism
- Additive central nervous system depression when co-administered with alcohol or other CNS depressants
Curated Content: Needs Vetting Before Put to Clinical Use